Send the following on WhatsApp
Continue to ChatI liked this article on M3 India: Canagliflozin reduces the risk of End-Stage Kidney Disease in T2DM patients:Results from the landmark trial(CREDENCE). Have a read: https://www.m3india.in/contents/editor_pick/canagliflozin-reduces-the-risk-of-end-stage?utm_campaign=unset&utm_medium=share&utm_source=ref_wa